Sagility, the Bengaluru-based healthcare operations company, told the exchanges late on Wednesday that it has bought a small US firm called Chirok Health. The Sagility Chirok Health acquisition is worth up to US$32.35 million in cash, and the filing says the deal was completed on October 21, 2026, the same day the agreement was signed.
The cheque isn’t large. What it does is tell us where the company wants to grow: on the hospital and doctor side of US healthcare, not just with insurers.
In this article
Sagility Chirok Health acquisition: the deal terms
According to the Regulation 30 disclosure filed with NSE, the buyer is Sagility (US) Holdings Inc., a wholly owned subsidiary. It is picking up 100% of Chirok Health LLC. The money splits into two parts:
- An upfront payment of US$20.0 million at closing, subject to the usual closing adjustments.
- Contingent consideration of up to US$12.35 million, payable only if specified performance milestones are met.
The filing says no government or regulatory approvals are needed, and that the deal isn’t a related-party transaction. The promoter group has no interest in Chirok.
What Chirok Health actually does
Chirok is headquartered in Tennessee. The filing says it was incorporated in 2019, while the company’s press release describes it as founded in 2020. It works on clinical documentation integrity, medical coding, audit and quality assurance, and revenue cycle management, run on its own workflow platform called CHEMP.
In plain terms, this is the work that makes sure what a doctor writes down gets coded correctly, so a hospital is paid properly and stays compliant. Sagility calls it the “mid-revenue cycle”. It already does the front end (patient access) and the back end (collections), and Chirok fills the gap in between.
The numbers behind the price
Chirok is small. The NSE filing puts its turnover at roughly:
- US$12.7 million in calendar 2023
- US$8.2 million in calendar 2024
- US$9.0 million in calendar 2025
So revenue fell sharply in 2024 and recovered only part of the way in 2025. By our own arithmetic, the full US$32.35 million works out to about 3.6 times the 2025 turnover, and the US$20 million upfront to about 2.2 times. The earn-out structure makes sense here. A seller with a bumpy revenue record gets the rest only if the business delivers.
Why Sagility is doing this
The company’s press release frames it as a step towards a full provider-services platform. Managing Director and Group CEO Ramesh Gopalan linked it to the recent CareSeed acquisition, saying the two deals together help clients with quality outcomes, reimbursement and value-based care. Chirok founder and CEO Kanar Kokoy said existing clients would keep the same specialised support.
The investor note filed alongside the release lists four reasons: a fuller provider revenue-cycle offering, cross-selling into each other’s clients, more risk-adjustment capability for health plans, and a team of clinical documentation and coding specialists.
What it means for investors
Chirok’s revenue is small, so the thing to track is whether these bolt-ons start showing up as faster provider-segment growth in the coming quarters. Our guide on how to analyse quarterly results of a company covers what to look at. For another recent small acquisition by a listed Indian company, see our note on Zen Technologies’ Cogknit acquisition.
Sources: Sagility Regulation 30 disclosure and press release filed with NSE (October 21, 2026); Sagility press release on sagility.com (October 21, 2026).
Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before making any investment decision.
Leave a Reply
Join the conversation
Commenting is open to registered readers. Sign up with just your email — no password needed, and it takes under a minute.
Sign up to comment Log in